Sandro Barni
#137,724
Most Influential Person Now
Sandro Barni's AcademicInfluence.com Rankings
Sandro Barniphilosophy Degrees
Philosophy
#7036
World Rank
#10186
Historical Rank
Logic
#4112
World Rank
#5365
Historical Rank
Download Badge
Philosophy
Sandro Barni's Degrees
- PhD Medical Sciences University of Milan
- Doctorate Medicine University of Milan
Why Is Sandro Barni Influential?
(Suggest an Edit or Addition)Sandro Barni's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. (2009) (563)
- Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis (2017) (515)
- Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. (2005) (447)
- Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. (2015) (431)
- A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care. (1999) (385)
- Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). (2000) (376)
- Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. (1999) (376)
- A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score (2012) (282)
- Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. (1999) (252)
- Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies (2016) (228)
- Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. (2014) (203)
- Prognostic role of lactate dehydrogenase in solid tumors: A systematic review and meta-analysis of 76 studies (2015) (183)
- Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients (2015) (183)
- The combined contribution of social support and coping strategies in predicting post‐traumatic growth: a longitudinal study on cancer patients (2011) (179)
- A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. (2014) (163)
- Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. (2014) (160)
- Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. (1994) (157)
- Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials. (2012) (157)
- FOLFIRINOX-Based Neoadjuvant Therapy in Borderline Resectable or Unresectable Pancreatic Cancer: A Meta-Analytical Review of Published Studies (2015) (156)
- Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. (1995) (152)
- Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial (2015) (150)
- Sexual dysfunction in treated breast cancer patients. (1997) (147)
- Is there a role for melatonin in the treatment of neoplastic cachexia? (1996) (137)
- Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. (1999) (135)
- Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. (2007) (134)
- Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. (2008) (134)
- FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis (2017) (132)
- Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. (1996) (129)
- Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). (2006) (127)
- The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis (2014) (123)
- Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. (2012) (117)
- A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first‐line treatment of advanced non‐small cell lung cancer patients in a poor clinical state (1997) (116)
- Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies. (2014) (116)
- The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials (2013) (115)
- Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials. (2017) (113)
- A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma. (2016) (107)
- Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel (2010) (106)
- A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. (1994) (103)
- Association of Obesity With Survival Outcomes in Patients With Cancer (2021) (100)
- Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. (2012) (100)
- Surgery of primary tumors in stage IV breast cancer: an updated meta-analysis of published studies with meta-regression (2012) (100)
- Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. (2011) (97)
- Endocrine and immune effects of melatonin therapy in metastatic cancer patients. (1989) (97)
- The biological significance of soluble interleukin-2 receptors in solid tumors. (1990) (97)
- Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study (2011) (95)
- Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. (1997) (94)
- Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. (2012) (92)
- Radical prostatectomy or radiotherapy in high-risk prostate cancer: a systematic review and metaanalysis. (2014) (92)
- A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) (1999) (88)
- Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin (1997) (86)
- Quality of Life in Breast and Colon Cancer Long-term Survivors: An Assessment with the Eortc Qlq-c30 and Sf-36 Questionnaires (2002) (85)
- A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms (1994) (85)
- The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis. (2017) (84)
- Stereotactic body radiotherapy for colorectal cancer liver metastases: A systematic review. (2018) (84)
- Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies (2012) (83)
- Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies. (2017) (83)
- A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer (2015) (80)
- Tumor necrosis factor in solid tumors: increased blood levels in the metastatic disease. (1992) (78)
- Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer). (1991) (76)
- Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. (2017) (75)
- Effects of media information on cancer patients' opinions, feelings, decision‐making process and physician‐patient communication (2004) (74)
- Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey (2013) (74)
- High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) (2004) (71)
- Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. (2007) (70)
- Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? (2015) (69)
- Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study (2020) (69)
- FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study (2012) (69)
- A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates. (1995) (68)
- Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis (2011) (68)
- Tumour Budding and Survival in Stage II Colorectal Cancer: a Systematic Review and Pooled Analysis (2015) (67)
- Clinical results with the pineal hormone melatonin in advanced cancer resistant to standard antitumor therapies. (1991) (66)
- A Randomized Study of Immunotherapy with Low-Dose Subcutaneous Interleukin-2 plus Melatonin Vs Chemotherapy with Cisplatin and Etoposide as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (1994) (66)
- Alternating versus continuous "FOLFIRI" in advanced colorectal cancer (ACC): A randomized "GISCAD" trial. (2006) (65)
- Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer. (2013) (63)
- Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic review and meta-analysis. (2014) (63)
- Efficacy and safety of levodropropizine and dihydrocodeine on nonproductive cough in primary and metastatic lung cancer. (1998) (63)
- Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. (2010) (63)
- Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Systematic Review With a Meta-Analysis. (2016) (62)
- Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin. (1992) (61)
- Predictive value of human papillomavirus in oropharyngeal carcinoma treated with radiotherapy: An updated systematic review and meta‐analysis of 30 trials (2014) (61)
- A study of the mechanisms involved in the immunostimulatory action of the pineal hormone in cancer patients. (1993) (60)
- Role of the pineal gland in the control of macrophage functions and its possible implication in cancer: a study of interactions between tumor necrosis factor-alpha and the pineal hormone melatonin. (1994) (60)
- Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials (2011) (59)
- Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract. (1993) (58)
- FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials. (2013) (58)
- Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials (2015) (57)
- Chemotherapy for metastatic breast cancer. (2005) (57)
- Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha. (1992) (56)
- Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis (2012) (56)
- Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey (2013) (56)
- FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial. (2018) (56)
- Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). (2002) (55)
- Prognostic Role of Primary Tumor Location in Non-Metastatic Gastric Cancer: A Systematic Review and Meta-Analysis of 50 Studies (2017) (54)
- Italian Oncological Pain Survey (IOPS): A Multicentre Italian Study of Breakthrough Pain Performed in Different Settings (2015) (54)
- Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings. (2009) (54)
- Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey (2014) (54)
- Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma (1996) (53)
- Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature (2017) (53)
- An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation (2002) (52)
- Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil. (2002) (51)
- Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancer (2013) (50)
- A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy (2016) (50)
- Epirubucin, cisplatin, and continuous infusion 5‐fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An italian group for the study of digestive tract cancer (GISCAD) report (1995) (50)
- Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis (2019) (49)
- Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone. (1997) (49)
- Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: a systematic review and pooled-analysis. (2015) (49)
- Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low‐dose epirubicin plus melatonin: A phase II study (1999) (48)
- Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis (2019) (48)
- Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. (2015) (48)
- Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. (2018) (47)
- Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma. (1994) (47)
- Pain and its treatment in hospitalized patients with metastatic cancer (2003) (47)
- Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials (2019) (47)
- Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma. (1994) (47)
- A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients. (1996) (47)
- Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2. (1991) (46)
- Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials (2013) (46)
- A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer (2001) (46)
- Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patients. (1996) (46)
- Clinical development of mTor inhibitors for renal cancer (2017) (46)
- Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer. (1992) (46)
- Patient performance status and cancer immunotherapy efficacy: a meta-analysis (2018) (45)
- Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients (2017) (45)
- The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study. (2014) (45)
- Increased Level of Soluble Interleukin-2 Receptor in Advanced Solid Tumors: A Preliminary Study (1988) (45)
- Circulating dendritic cells in early and advanced cancer patients: diminished percent in the metastatic disease. (1999) (44)
- Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results. (1993) (44)
- Oxaliplatin-based chemotherapy: a new option in advanced hepatocellular carcinoma. a systematic review and pooled analysis. (2014) (43)
- KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials (2013) (43)
- Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. (2017) (43)
- Different Toxicity of Cetuximab and Panitumumab in Metastatic Colorectal Cancer Treatment: A Systematic Review and Meta-Analysis (2018) (43)
- Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors. (1995) (42)
- Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). (1998) (41)
- Microsatellite Instability and Survival in Stage II Colorectal Cancer: A Systematic Review and Meta-analysis (2019) (41)
- Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. (2014) (40)
- A Rare Case of Metastatic Pancreatic Hepatoid Carcinoma Treated with Sorafenib (2012) (40)
- The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib (2015) (40)
- Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies. (2017) (40)
- Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta‐analysis (2016) (40)
- Venous thromboembolism and cancer: new issues for an old topic. (2003) (39)
- A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). (2000) (39)
- Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis (2018) (39)
- A pooled analysis of 2618 patients treated with trastuzumab beyond progression for advanced breast cancer. (2013) (38)
- Efficacy of the concomitant administration of the pineal hormone melatonin in cancer immunotherapy with low-dose IL-2 in patients with advanced solid tumors who had progressed on IL-2 alone. (1994) (38)
- Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials (2012) (38)
- A novel perspective for an orphan problem: old and new drugs for the medical management of malignant ascites. (2011) (37)
- Lower survival in metastatic cancer patients with reduced interleukin-2 blood concentrations. Preliminary report. (1991) (37)
- Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients (2014) (37)
- The Modified Glasgow Prognostic Score and Survival in Colorectal Cancer: A Pooled Analysis of the Literature. (2015) (37)
- Serum Levels of Insulin-Like Growth Factor-I in Operable Breast Cancer in Relation to the Main Prognostic Variables and their Perioperative Changes in Relation to those of Prolactin (1994) (37)
- Role of HER2-neu as a prognostic factor for survival and relapse in pT1a–bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis (2012) (36)
- The risk for anemia with targeted therapies for solid tumors. (2012) (36)
- Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients. (1992) (36)
- Adjuvant radiotherapy for Merkel cell carcinoma: A systematic review and meta-analysis. (2019) (36)
- Clinical Study of Melatonin in Untreatable Advanced Cancer Patients (1987) (36)
- Hepatic resection for gastric cancer liver metastases: A systematic review and meta‐analysis (2015) (36)
- Addition of radiotherapy to the primary tumour in oligometastatic NSCLC: A systematic review and meta-analysis. (2018) (36)
- Outcome of head compared to body and tail pancreatic cancer: a systematic review and meta-analysis of 93 studies. (2019) (35)
- Five-Year Survival Results of Subcutaneous Low-Dose Immunotherapy with Interleukin-2 Alone in Metastatic Renal Cell Cancer Patients (2000) (35)
- Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies (2018) (35)
- Analysis of T helper and suppressor lymphocyte subsets in relation to the clinical stage of solid neoplasms. (1990) (35)
- Differences of vascular endothelial growth factor (VEGF) expression between liver and abdominal metastases from colon cancer. Implications for the treatment with VEGF inhibitors (2004) (34)
- Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. (2012) (34)
- Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis (2012) (34)
- Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial. (2019) (34)
- Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta‐analysis (2018) (34)
- Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). (2003) (34)
- A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breast-cancer patients. (1995) (33)
- Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials. (2017) (33)
- A biological study on the efficacy of low-dose subcutaneous interleukin-2 plus melatonin in the treatment of cancer-related thrombocytopenia. (1995) (32)
- Awareness of cancer, satisfaction with care, emotional distress, and adjustment to illness: an Italian multicenter study (2015) (32)
- Clinical and Molecular Predictors of PD‐L1 Expression in Non–Small‐Cell Lung Cancer: Systematic Review and Meta‐analysis (2018) (32)
- Activation of the Complement System during Immunotherapy of Cancer with Interleukin-2: A Possible Explanation of the Capillary Leak Syndrome (1990) (32)
- A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. (2017) (32)
- In vitro modulatory effects of interleukin‐3 on macrophage activation induced by interleukin‐2 (1993) (32)
- Acquired and inherited risk factors for the developing of venous thromboembolism in cancer patients receiving adjuvant chemotherapy: A prospective trial. (2016) (32)
- Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC. (2005) (32)
- Postoperative increase in soluble interleukin‐2 receptor serum levels as predictor for early recurrence in non‐small cell lung carcinoma (1992) (32)
- The emerging issue of ratio of metastatic to resected lymph nodes in gastrointestinal cancers: an overview of literature. (2011) (31)
- Patients' opinions, feelings, and attitudes after a campaign to promote the Di Bella therapy (1999) (31)
- Subcutaneous Therapy with Low-Dose Interleukin-2 plus the Neurohormone Melatonin in Metastatic Gastric Cancer Patients with Low Performance Status (1993) (30)
- Decreased apoptosis in fatty livers submitted to subnormothermic machine-perfusion respect to cold storage (2011) (30)
- Prognostic Factors of Overall Survival in Upper Urinary Tract Carcinoma: A Systematic Review and Meta-analysis. (2017) (30)
- Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: a meta-analysis of 2 randomized trials. (2011) (29)
- Targeted therapies for the treatment of breast cancer in the post-trastuzumab era. (2008) (29)
- Surveillance or Adjuvant Treatment With Chemotherapy or Radiotherapy in Stage I Seminoma: A Systematic Review and Meta-Analysis of 13 Studies. (2015) (29)
- Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. (2017) (29)
- Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer. (1999) (29)
- Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis (2015) (29)
- 5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials (2012) (29)
- Clinical outcome and molecular characterization of brain metastases from esophageal and gastric cancer: a systematic review (2017) (28)
- Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE). (2013) (28)
- Endocrine effects of a 24-hour intravenous infusion of interleukin-2 in the immunotherapy of cancer. (1990) (28)
- Weekly Doxorubicin Chemotherapy for Breast Cancer in Pregnancy. A Case Report (1992) (28)
- Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. (2016) (28)
- Pineal gland and tumor cell kinetics: serum levels of melatonin in relation to Ki-67 labeling rate in breast cancer. (1990) (28)
- Intracavitary Administration of Interleukin-2 as Palliative Therapy for Neoplastic Effusions (1992) (28)
- Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter Analysis (2018) (27)
- Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non–Small-Cell Lung Cancer in Elderly Patients (2014) (27)
- A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study (2018) (27)
- A Randomized Study of Low-Dose Interleukin-2 Subcutaneous Immunotherapy versus Interleukin-2 plus Interferon-Alpha as First Line Therapy for Metastatic Renal Cell Carcinoma (1993) (27)
- Cisplatin or Not in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis (2013) (27)
- Efficacy of Oxaliplatin-based Chemotherapy+Bevacizumab as First-line Treatment for Advanced Colorectal Cancer: A Systematic Review and Pooled Analysis of Published Trials (2015) (26)
- Combination of radiotherapy and immunotherapy for brain metastases: A systematic review and meta-analysis. (2019) (26)
- Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials (2013) (26)
- Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel. (2007) (26)
- Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study. (2016) (26)
- Correlation of Serum Interleukin-2 Levels, Soluble Interleukin-2 Receptors and T Lymphocyte Subsets in Cancer Patients (1990) (26)
- High- versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: A ‘GISCAD’ phase III study (1997) (26)
- Platinum rechallenge in patients with advanced NSCLC: a pooled analysis. (2013) (25)
- SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab (2017) (25)
- Dipeptidylpeptidase-IV, a key enzyme for the degradation of incretins and neuropeptides: activity and expression in the liver of lean and obese rats (2012) (25)
- Modulation of interleukin-2-induced macrophage activation in cancer patients by the pineal hormone melatonin. (1991) (25)
- Careful Breakthrough Cancer Pain Treatment through Rapid-Onset Transmucosal Fentanyl Improves the Quality of Life in Cancer Patients: Results from the BEST Multicenter Study (2020) (24)
- A randomized, placebo-controlled, phase I/II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (CRC) who had received previous front-line systemic therapy. (2013) (24)
- Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials (2016) (24)
- Prediction of recurrence in operable breast cancer by postoperative changes in prolactin secretion. (1995) (23)
- Importance of adherence to guidelines in breast cancer clinical practice. The Italian experience (AIOM). (2011) (23)
- Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination. (2000) (23)
- Effects of a preoperative therapy with interleukin-2 on surgery-induced lymphocytopenia in cancer patients. (1992) (23)
- Association of CDX2 Expression With Survival in Early Colorectal Cancer: A Systematic Review and Meta‐analysis (2018) (23)
- Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin. (1993) (22)
- Enzalutamide after docetaxel and abiraterone acetate treatment in prostate cancer: a pooled analysis of 10 case series. (2015) (22)
- One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis (2018) (22)
- Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients (1997) (22)
- A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma. (2018) (22)
- Axillary dissection compared to sentinel node biopsy for the treatment of pathologically node-negative breast cancer: a meta-analysis of four randomized trials with long-term follow up (2012) (22)
- Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension. (1990) (22)
- The effect of low-molecular-weight heparin in cancer patients: the mirror image of survival? (2014) (22)
- Oncostress: Evaluation of Burnout in Lombardy (1996) (21)
- Activity of fulvestrant in HER2-overexpressing advanced breast cancer. (2010) (21)
- Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study. (2009) (21)
- A systematic review of raltitrexed-based first-line chemotherapy in advanced colorectal cancer (2014) (21)
- The pineal hormone melatonin in hematology and its potential efficacy in the treatment of thrombocytopenia. (1996) (21)
- Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers. (2000) (21)
- Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. (2019) (21)
- A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience (2017) (20)
- Effect of antitumor surgery on soluble interleukin-2 receptor serum levels. (1991) (20)
- TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape? (2016) (20)
- FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials (2013) (20)
- Enhanced secretion of tumour necrosis factor in patients with myocardial infarction. (1992) (20)
- Ten Years Experience with Ewing's Sarcoma (1977) (20)
- Radioendocrine Therapy of Brain Tumors with the Long Acting Opioid Antagonist Naltrexone in Association with Radiotherapy (1993) (19)
- Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor‐positive, advanced breast cancer: A real‐world experience (2018) (19)
- A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice (2013) (19)
- Intracavitary therapy of neoplastic effusions with cytokines: comparison among interferon α, β and interleukin-2 (2004) (19)
- Relation between macrophage and T helper-2 lymphocyte functions in human neoplasms: neopterin, interleukin-10 and interleukin-6 blood levels in early or advanced solid tumors. (1995) (19)
- Treatment of cancer-related thrombocytopenia by low-dose subcutaneous interleukin-2 plus the pineal hormone melatonin: a biological phase II study. (1995) (19)
- Amplification of eosinophilia by melatonin during the immunotherapy of cancer with interleukin-2. (1993) (19)
- Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better (2012) (18)
- Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta‐Analysis (2017) (18)
- Acute effects of pamidronate administration on serum levels of interleukin-6 in advanced solid tumour patients with bone metastases and their possible implications in the immunotherapy of cancer with interleukin-2. (1997) (18)
- Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPiO study. (2019) (18)
- Salvage Therapy in Advanced Adult Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis of Randomized Trials. (2017) (18)
- Prevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatonin (1996) (18)
- Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers. (2017) (18)
- Adjuvant chemotherapy for rectal cancer. (2015) (17)
- Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. (2011) (17)
- Evidence for altered opioid activity in patients with cancer. (1987) (17)
- Predictive Factors for Reclassification and Relapse in Prostate Cancer Eligible for Active Surveillance: A Systematic Review and Meta-analysis. (2016) (17)
- Progress Report on the Palliative Therapy of 100 Patients with Neoplastic Effusions by Intracavitary Low-Dose Interleukin-2 (2001) (17)
- Polychemotherapy or gemcitabine in advanced pancreatic cancer: a meta-analysis. (2014) (17)
- Thrombopoietic Property of the Pineal Hormone Melatonin (1999) (17)
- Pineal‐Opioid System Interactions in the Control of Immunoinflammatory Responses (1994) (17)
- Vinorelbine as Single Agent in Pretreated Patients with Advanced Breast Cancer (1994) (17)
- Respiratory distress syndrome in patients with advanced cancer treated with pentoxifylline: a randomized study (1993) (17)
- Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials (2011) (16)
- Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study. (2015) (16)
- Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11,585 patients (2015) (16)
- Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials. (2015) (16)
- Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer (2013) (16)
- Neuroimmunotherapy with Subcutaneous Low-Dose Interleukin-2 and the Pineal Hormone Melatonin as a Second-Line Treatment in Metastatic Colorectal Carcinoma (1992) (16)
- Preliminary study on modulation of the biological effects of tumor necrosis factor-alpha in advanced cancer patients by the pineal hormone melatonin. (1994) (16)
- Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer : A low cost effective regimen (2002) (16)
- Bisphosphonates and metastatic bone disease. (2006) (16)
- A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour (1995) (16)
- Does patient education work in breast cancer? Final results from the global CARIATIDE study. (2015) (16)
- Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: results from the Italian observational "SUN" (Survey on the lUng cancer maNagement) study. (2011) (16)
- Optimizing use of opiates in the management of cancer pain (2006) (16)
- Vascular Endothelial Growth Factor and p53 Expressions in Liver and Abdominal Metastases from Colon Cancer (2003) (15)
- A study on the relationship between the pineal gland and the opioid system in patients with cancer preliminary considerations (1988) (15)
- Inhibition of tumor necrosis factor-alpha secretion by pentoxifylline in advanced cancer patients with abnormally high blood levels of tumor necrosis factor-alpha. (1993) (15)
- Cardiotoxicity of antiemetic drugs in oncology: An overview of the current state of the art. (2016) (15)
- Efficacy and safety of eribulin in taxane-refractory patients in the 'real world'. (2017) (15)
- Bevacizumab in advanced breast cancer: an opportunity as second-line therapy? (2012) (15)
- Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients (2012) (15)
- P84 High dose epirubicin and cyclophosphamide (EC) vs cyclophosphamide, methotrexate, fluorouracil (CMF) as adjuvant chemotherapy in high risk premenopausal breast cancer patients (PTS). A prospective randomized trial (1998) (15)
- Effects of a preoperative course of interleukin-2 on surgical and immunobiological variables in patients with colorectal cancer: a phase 2 study. (1993) (15)
- Position paper on management of iron deficiency in adult cancer patients (2017) (15)
- Neoadjuvant imatinib in a locally advanced gastrointestinal stromal tumour (GIST) of the rectum: a rare case of two GISTs within a family without a familial GIST syndrome. (2007) (15)
- Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. (2015) (15)
- Non-cancer-related mortality after cisplatin-based adjuvant chemotherapy for non-small cell lung cancer: a study-level meta-analysis of 16 randomized trials (2013) (14)
- Diagnosis, Management and Clinical Outcome of Bone Metastases in Breast Cancer Patients: Results from a Prospective, Multicenter Study (2007) (14)
- Prognostic factors after R0 resection of colorectal cancer liver metastases: A systematic review and pooled-analysis. (2016) (14)
- Overview of different available chemotherapy regimens combined with radiotherapy for the neoadjuvant and definitive treatment of esophageal cancer (2017) (14)
- Neoadjuvant dose-dense chemotherapy for locally advanced breast cancer: a meta-analysis of published studies (2016) (14)
- Second-Line Therapy with Interferon-Alpha plus Vinblastine in Metastatic Renal Cell Cancer Patients Progressed under Interleukin-2 Subcutaneous Immunotherapy (1995) (14)
- Effects of radical mastectomy on prolactin blood levels in patients with breast cancer. (1987) (14)
- Alteration of Opioid Peptide Circadian Rhythm in Cancer Patients (1988) (14)
- Relation between Lymphocyte Subpopulations and Pineal Function in Patients with Early or Metastatic Cancer (1988) (14)
- Melatonin Increase as Predictor for Tumor Objective Response to Chemotherapy in Advanced Cancer Patients (1988) (14)
- Efficacy and tolerability of cancer neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin - a progress report of 200 patients with advanced solid neoplasms. (1995) (14)
- Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy. (1998) (14)
- Thrombin generation predicts early recurrence in breast cancer patients (2020) (13)
- Postoperative Hyperprolactinemia Could Predict Longer Disease-Free and Overall Survival in Node-Negative Breast Cancer Patients (2002) (13)
- A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group. (1997) (13)
- Neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin in AIDS patients with CD4 cell number below 200/mm3: a biological phase-II study. (1995) (13)
- The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer (2015) (13)
- Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based? (2009) (13)
- Corrigendum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases (2016) (13)
- Surrogate end points and postprogression survival in renal cell carcinoma: an analysis of first-line trials with targeted therapies. (2013) (13)
- PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy (2021) (13)
- Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study (2016) (13)
- Decrease in cholesterol levels during the immunotherapy of cancer with interleukin-2. (1991) (13)
- Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials (2016) (12)
- Serum levels of soluble interleukin-2 receptors and their relation to lymphocyte subpopulations in patients with metastatic solid tumours. (1989) (12)
- Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study (2019) (12)
- Neuroimmunomodulation in Cancer Patients: Correlations between Melatonin and ß-Endorphin Blood Levels and T Helper/Suppressor Ratio (1988) (12)
- Clinical Efficacy of the Aromatase Inhibitor Anastrozole in Relation to Prolactin Secretion in Heavily Pretreated Metastatic Breast Cancer (1998) (12)
- The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer. (2019) (12)
- Effectiveness of First-Line Bevacizumab in Metastatic Colorectal Cancer: The Observational Cohort Study GRETA. (2018) (12)
- Immunoendocrine Therapy with Interleukin-2 (IL-2) and Medroxyprogesterone Acetate (MPA): A Randomized Study with or without MPA in Metastatic Renal Cancer Patients during IL-2 Maintenance Treatment after Response or Stable Disease to IL-2 Subcutaneous Therapy (1993) (12)
- Modified schedules of DCF chemotherapy for advanced gastric cancer: a systematic review of efficacy and toxicity (2017) (12)
- Vinorelbine With Capecitabine, an Evergreen Doublet for Advanced Breast Cancer: A Systematic Literature Review and Pooled-Analysis of Phase II-III Studies. (2016) (12)
- Borderline resectable pancreatic cancer: More than an anatomical concept. (2017) (12)
- In vivo biological results of the association between interleukin-2 and interleukin-3 in the immunotherapy of cancer. (1993) (12)
- Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer (2019) (12)
- What else in gemcitabine-pretreated advanced pancreatic cancer? An update of second line therapies. (2010) (12)
- Intracavitary therapy of neoplastic effusions with cytokines: comparison among interferon alpha, beta and interleukin-2. (1995) (12)
- Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study (2005) (12)
- Effects of granulocyte-macrophage colony stimulating factor on soluble interleukin-2 receptor serum levels and their relation to neopterin and tumor necrosis factor-alpha in cancer patients. (1993) (12)
- A patient presenting nasal septum perforation during bevacizumab-containing chemotherapy for advanced breast cancer (2011) (11)
- Impact on Survival of Timing and Duration of Adjuvant Chemotherapy in Radically Resected Gastric Cancer (2016) (11)
- Neuroendocrine Effects of Subcutaneous Interleukin-2 Injection in Cancer Patients (1991) (11)
- Cetuximab/irinotecan-chemotherapy in KRAS wild-type pretreated metastatic colorectal cancer: a pooled analysis and review of literature. (2013) (11)
- Oral idarubicin and cyclophosphamide for metastatic breast cancer in elderly patients (1998) (11)
- Blood Concentrations of Tumor Necrosis Factor-Alpha in Malignant Lymphomas and Their Decrease as a Predictor of Disease Control in Response to Low-Dose Subcutaneous Immunotherapy with Interleukin-2 (1999) (11)
- Agreement between oncology guidelines and clinical practice in Italy: the 'right' program. A project of the Italian Association of Medical Oncology (AIOM). (2007) (11)
- Number of lung resections performed and long-term mortality rates of patients after lung cancer surgery: evidence from an Italian investigation. (2020) (11)
- TAS-102 (Lonsurf) for the Treatment of Metastatic Colorectal Cancer. A Concise Review. (2016) (11)
- Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. (2015) (11)
- Increased Blood Concentrations of Interleukin-12 are Associated with a Longer Survival in Untreatable Metastatic Solid Tumor Patients: Preliminary Observations (1997) (11)
- Risk of second primary tumors in GIST survivors: A systematic review and meta-analysis. (2019) (10)
- Anti‐EGFR–targeting agents in recurrent or metastatic head and neck carcinoma: A meta‐analysis (2012) (10)
- Benefit of adjuvant chemotherapy in elderly ER-negative breast cancer patients: benefits and pitfalls (2010) (10)
- Clinical Efficacy of Cancer Subcutaneous Immunotherapy with Interleukin-2 in Relation to the Pretreatment Levels of Tumor Growth Factor Insulin-Like Growth Factor-1 (1995) (10)
- Effects of One-Year Adjuvant Treatment with Tamoxifen on Bone Mineral Density in Postmenopausal Breast Cancer Women (1996) (10)
- Toxicity of targeted therapies in elderly patients (2008) (10)
- The Pineal Gland and Breast Cancer: Serum Levels of Melatonin in Patients with Mammary Tumors and Their Relation to Clinical Characteristics (1989) (10)
- Dehydroepiandrosterone Sulfate (DHEAS) Secretion in Early and Advanced Solid Neoplasms: Selective Deficiency in Metastatic Disease (1998) (10)
- Prevention by L-Carnitine of Interleukin-2-Related Cardiac Toxicity during Cancer Immunotherapy (1993) (10)
- Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review. (2017) (10)
- Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors (2011) (10)
- [Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy]. (2015) (10)
- A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first‐line treatment in patients with poor‐prognosis small cell lung carcinoma (2005) (10)
- Effects of granulocyte-macrophage colony stimulating factor on cortisol, growth hormone, prolactin and melatonin in cancer patients (short communication). (1992) (9)
- Obesity paradox in patients with cancer: A systematic review and meta-analysis of 6,320,365 patients (2020) (9)
- H2020 and Beyond: Skip Discrepancy between Theory and Practice of Personalized Medicine. A Position Paper by the Italian Society of Personalized Medicine. (2016) (9)
- Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy (2019) (9)
- Preventing or treating anti-EGFR related skin rash with antibiotics? (2016) (9)
- Postoperative increase in soluble interleukin-2 receptor serum levels as predictor for early recurrence in non-small cell lung carcinoma. (1993) (9)
- Dipeptidylpeptidase-IV Activity and Expression Reveal Decreased Damage to the Intrahepatic Biliary Tree in Fatty Livers Submitted to Subnormothermic Machine-Perfusion Respect to Conventional Cold Storage (2014) (9)
- Characterization of Cancer-Related Disseminated Intravascular Coagulation in Relation to Tumor Necrosis Factor-Alpha Blood Concentrations: Possible Therapeutic Role of Pentoxifylline (1996) (9)
- The extension of disease is associated to an increased risk of venous thromboembolism (VTE) in patients with gastrointestinal (GI) carcinoma (2006) (9)
- A Weekly Schedule of Epirubicin in Pretreated Advanced Breast Cancer (1993) (9)
- Cisplatin versus cetuximab plus concomitant radiotherapy in locally advanced head and neck cancer: A meta-analysis of published trials. (2014) (9)
- FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study. (2015) (9)
- Prolactin Response to Thyrotropin-Releasing Hormone in Early and Advanced Human Breast Cancer (1986) (9)
- Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab (2020) (9)
- Breast cancer, locally advanced and metastatic (2012) (9)
- Altered alkaline phosphatase activity in obese Zucker rats liver respect to lean Zucker and Wistar rats discussed in terms of all putative roles ascribed to the enzyme (2011) (9)
- Ki-67 Labeling Index in Breast Cancer (1989) (9)
- Blood Levels of IGF-I in Non-Small Cell Lung Cancer: Relation to Clinical Data (1991) (9)
- Radical treatment of oligometastatic non-small cell lung cancer: Ready for prime time? (2017) (9)
- Progression of intramedullary metastasis during perioperative cessation of sunitinib (2010) (9)
- Endocrine and Clinical Effects of an Lhrh Analogue in Pretreated Advanced Breast Cancer (1988) (9)
- Immunotherapy with subcutaneous low dose interleukin-2 plus melatonin as salvage therapy of heavily chemotherapy-pretreated ovarian cancer. (1996) (8)
- Bevacizumab (BV) maintenance therapy significantly delays disease progression (PD) or death compared with placebo (PL) in the AVADO trial (BV + docetaxel [D] vs D + PL in 1st-line HER2-negative locally recurrent [LR] or metastatic breast cancer [mBC]). (2009) (8)
- Acute endocrine effects of interleukin-12 in cancer patients. (1997) (8)
- Weekly Docetaxel in Pretreated Metastatic Breast Cancer Patients: A Phase I-II Study (2005) (8)
- Effects of hypertension on cancer survival: A meta‐analysis (2021) (8)
- A Study of Thyroid Function in Cancer Cachexia (1989) (8)
- Sequential methotrexate and 5-fluorouracil as second-line chemotherapy for advanced colorectal cancer patients pretreated with 5-fluorouracil and leucovorin: a GISCAD study. (1996) (8)
- Mitoxantrone as a Single Agent in Pretreated Metastatic Breast Cancer: Effects on T Lymphocyte Subsets and Their Relation to Clinical Response (1991) (8)
- Concurrent Carboplatin/5Fu and Radiotherapy Compared to Radiotherapy Alone in Locally Advanced Cervical Carcinoma: A Case-Control Study (1997) (8)
- The impact of cetuximab on the gemcitabine/cisplatin combination in first-line treatment of EGFR-positive advanced pancreatic cancer (APC): A randomized phase II trial of GISCAD (2007) (8)
- Prevention of interleukin-2-induced thrombocytopenia during the immunotherapy of cancer by a concomitant administration of the pineal hormone melatonin. (1995) (8)
- From the trastuzumab era to new target therapies: beyond revolution. (2007) (8)
- Immunotherapy with Low-Dose Subcutaneous Interleukin-2 plus Beta-Interferon as a Second-Line Therapy for Metastatic Colorectal Carcinoma (1993) (8)
- Burden of advanced breast cancer for patients and caregivers in Europe: comparison of two treatment forms of vinorelbine, oral and intravenous (2016) (7)
- Catheter-related bloodstream infections, part I: pathogenesis, diagnosis, and management. (2002) (7)
- Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) (1999) (7)
- Growth Factors: Thrombopoietic Property of the Pineal Hormone Melatonin. (1999) (7)
- Correlation between pretreatment serum levels of neopterin and response to interleukin-2 immunotherapy in cancer patients. (1995) (7)
- Attitude of Italian medical oncologists toward palliative care for patients with advanced cancer: results of the SIO project (2011) (7)
- Oxaliplatin in colon cancer. (2004) (7)
- 4th Mediterranean Multidisciplinary Course on Iron Anemia April 29th–30th 2016, Madrid, Spain (2016) (7)
- Salvage treatment for testicular cancer with standard- or high-dose chemotherapy: a systematic review of 59 studies (2017) (7)
- The Italian Rare Pancreatic Exocrine Cancer Initiative (2019) (7)
- A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer. (1999) (7)
- Improving chemotherapy capacity by switching from i.v. to oral vinorelbine (2010) (7)
- Treatment of venous thromboembolism with tinzaparin in oncological patients. (2019) (6)
- Acute Effects of Various Chemotherapeutic Combinations on Hypophyseal and Pineal Hormone Secretions in Cancer Patients (1987) (6)
- Overall Survival in Metastatic Breast Cancer Patients in the Third Millennium: Results of the COSMO Study. (2020) (6)
- Synthetic enkephalin analog in the treatment of cancer chemotherapy-induced vomiting. (1987) (6)
- Adjuvant Systemic Therapies in Patients with Colorectal Cancer: An Audit on Clinical Practice in Italy (2005) (6)
- PROSE: Randomized proteomic stratified phase III study of second line erlotinib versus chemotherapy in patients with inoperable non-small cell lung cancer (NSCLC). (2011) (6)
- Multigene tests for breast cancer: the physician’s perspective (2021) (6)
- Failures (Cause and Time) of Radiotherapy in Oral Cancer (1978) (6)
- Double modulation of 5-fluorouracil in advanced colorectal cancer with low-dose interferon-α2b and folinic acid. The “GISCAD” experience (1994) (6)
- Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate (2011) (6)
- Changes in T lymphocyte subsets after single dose epirubicin. (1990) (6)
- A Radiologic Study by CT Scan of Pineal Size in Cancer Patients: Correlation to Melatonin Blood Levels (1989) (6)
- Clinical Activity and Cardiac Tolerability of Non-Pegylated Liposomal Doxorubicin in Breast Cancer: A Synthetic Review (2011) (6)
- Blood Concentrations of Interleukin-15 in Cancer Patients and Their Variations during Interleukin-2 Immunotherapy: Preliminary Considerations (1998) (6)
- FOLFIRI with cetuximab or bevacizumab: FIRE-3. (2014) (6)
- Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a systematic review of randomized trials. (2017) (6)
- High-versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: a 'GISCAD' phase III study. Italian Group for the Study of Digestive Tract Cancer. (1997) (6)
- Gastrointestinal tumors, non-colorectal (2012) (6)
- [Clinical response and survival in metastatic renal carcinoma during subcutaneous administration of interleukin-2 alone. Subcutaneous Il-2 in renal carcinoma]. (1997) (5)
- Serum interleukin-2 levels in relation to the neuroendocrine status in cancer patients. (1990) (5)
- Prognostic Value of Lymphography in Cervical Cancer (1978) (5)
- A. Manni, M.F. Verderame (eds). Selective Estrogen Receptor Modulators: Research and Clinical Applications (2002) (5)
- Single-Agent Epirubicin as Primary Chemotherapy in T2–T3, N0–N2, M0 Breast Carcinoma: 6-Year Follow-Up (2004) (5)
- Endocrine Effects of Granulocyte Colony-Stimulating Factor in Cancer Patients (1995) (5)
- Preoperative neuroimmunotherapy with subcutaneons low-dose interleukin-2 and melatonin in patients with gastrointestinal tumors - its efficacy in preventing surgery-induced lymphocytopenia. (1995) (5)
- Oral etoposide as second-line chemotherapy for colorectal cancer: a GISCAD study. Gruppo Italiano Studio Carcinomi Apparato Digerente. (1995) (5)
- Cytokine regulation of iron metabolism: effect of low-dose interleukin-2 subcutaneous therapy on ferritin, transferrin and iron blood concentrations in cancer patients. (1993) (5)
- Serum levels of interleukin-2 in cancer patients: Preliminary considerations (1989) (5)
- Postoperative hyperprolactinaemia and early recurrence rate in breast cancer. (1990) (5)
- Correlation between Changes in Prolactin and Melatonin Serum Levels after Radical Mastectomy (1987) (5)
- Efficacy of Eribulin mesylate in older patients with breast cancer: A pooled analysis of clinical trial and real-world data. (2020) (5)
- Natural history of malignant bone disease in renal cancer: Final results of an Italian bone metastases survey. (2012) (5)
- A study of interactions among markers of macrophage functions in metastatic solid tumors: neopterin levels in relation to those of tumor necrosis factor-alpha and of soluble interleukin-2 receptors. (1994) (5)
- Catheter-related bloodstream infections, part II: specific pathogens and prevention. (2003) (5)
- Vinorelbine and Carboplatin in Inoperable Non-Small Cell Lung Cancer: A Monoinstitutional Phase II Study (2003) (5)
- Final results of a randomized, double-blind, phase II study of gemcitabine plus vandetanib or plus placebo in the treatment of advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) elderly patients (ZELIG study NCT00753714). (2012) (4)
- Individual patients data analysis (IPD) of three randomized studies comparing erlotinib (E) with chemotherapy (CT) in patients with advanced wild-type epidermal growth factor receptor (wtEGFR) non-small cell lung cancer (NSCLC). (2015) (4)
- Is overall survival still the primary endpoint in maintenance non-small cell lung cancer studies? An analysis of phase III randomised trials. (2013) (4)
- Feasibility of Eribulin Mesylate in older patients with locally advanced or metastatic breast cancer: A post-hoc analysis of the ESEMPiO study. (2019) (4)
- Modulation of Tumor Necrosis Factor‐α (TNF‐α) Toxicity by the Pineal Hormone Melatonin (MLT) in Metastatic Solid Tumor Patients (1995) (4)
- Biological agents alone or in combination as second-line therapy in advanced non-small-cell lung cancer: systematic review of randomized studies (2012) (4)
- Risk of Primary Tumor Sidedness as a Criterion for Screening, Diagnostic Colonoscopy, and Surveillance Intervals-Reply. (2017) (4)
- Cancer: New Needs, New Models. Is It Time for a Community Oncologist? Another Brick in the Wall (2021) (4)
- Long response to eribulin in breast cancer: a case report. (2015) (4)
- Tamoxifen-Induced Sexual Dysfunction in a Breast Cancer Patient: A Case Report (1998) (4)
- Is the oncotype DX test useful in elderly breast cancer patients: a subgroup analysis of real-life Italian PONDx study (2021) (4)
- Benefit of tamoxifen in estrogen receptor positive DCIS of the breast. (2012) (4)
- Major innovations and clinical applications of disodium-levofolinate: a review of available preclinical and clinical data (2019) (4)
- Weekly paclitaxel, 5-fluorouracil and folinic acid with granulocyte colony-stimulating factor support in metastatic breast cancer patients: a phase II study (2006) (4)
- Evaluation of the Cardiovascular Toxicity Related to Cancer Immunotherapy with Interleukin-2 by Monitoring Atrial Natriuretic Peptide Secretion: A Case Report (1990) (4)
- Vinorelbine (VNR) in pretreated advanced breast cancer (ABC) (1993) (4)
- The Role of 5-Fluorouracil (5-FU) Reintroduction with Irinotecan or Oxaliplatin in Truly 5-FU-Refractory Advanced Colorectal Cancer Patients (2005) (4)
- Prognostic factors in KRAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with biweekly cetuximab (C) plus irinotecan, fluorouracil, and leucovorin (FOLFIRI): A phase II study. (2013) (4)
- Alterations of pineal gland and of T lymphocyte subsets in metastatic cancer patients: preliminary results. (1989) (4)
- Natural history of malignant bone disease in colorectal cancer: Final results of a large Italian “bone metastases” survey (2011) (4)
- Phase II Study of the Activity and Tolerability of a Combined Regimen of High-Dose Epirubicin and Cisplatin in Stage IIIb and IV Non-Small Cell Lung Cancer (1998) (4)
- Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. (2021) (4)
- Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil (2004) (4)
- [Therapy with melatonin does not suppress its endogenous production in healthy volunteers]. (1999) (4)
- Eribulin in 'field practice': an overview of the Italian experience. (2015) (4)
- The core components of cardio-oncology rehabilitation. (2021) (4)
- Improving chemotherapy capacity by switching from intravenous to oral vinorelbine: TAMINO, an international time and motion audit (2010) (4)
- Adjuvant chemotherapy with high dose epirubicin and cyclophosphamide (ec) vs cyclophosphamide, methotrexate, fluorouracil (CMF) in high risk premenopausal breast cancer patients (PTS). A prospective randomized trial. E (1997) (4)
- F27LDH as prognostic factor for survival in castration-resistant prostate cancer (CRPC): a systematic review and pooled analysis of the literature (2015) (4)
- Immunotherapy with low-dose interleukin-2 in association with melatonin as salvage therapy for metastatic soft tissue sarcomas. (1997) (3)
- A study of pineal-prolactin interaction: prolactin response to an acute melatonin injection in patients with hyperprolactinemia (1990) (3)
- More on Platelet-Rich Plasma Injections in Acute Muscle Injury (2014) (3)
- Effects of cancer chemotherapy on the relation between serum levels of soluble interleukin-2 receptors and CD4/CD8 ratio in patients with solid neoplasms. (1989) (3)
- Prolactin Secretion in Testicular Cancer Patients (1989) (3)
- Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti‐HER2 agents in the real world setting (2019) (3)
- PISCES trial: the end does not always justify the means. (2014) (3)
- Adjuvant bisphosphonates in patients with breast cancer: does the potency matter? (2015) (3)
- Changes in Circulating Immature and Mature Dendritic Cells During IL-2 Cancer Immunotherapy and Their Relation with Lymphocyte Increase and Clinical Response (2000) (3)
- Activity of fulvestrant in HER 2-overexpressing advanced breast cancer (2010) (3)
- [Association of laparoscopy and bone marrow biopsy in the staging of small-cell undifferentiated carcinoma of the lung. Evaluation of 116 consecutive cases]. (1982) (3)
- Gastric cancer: toward a cisplatin-free disease? (2014) (3)
- A clinical-study of immunotherapy versus endocrine therapy versus chemotherapy in the treatment of advanced pancreatic adenocarcinoma. (1994) (3)
- Bone metastases in biliary cancers: A multicenter retrospective survey (2018) (3)
- The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status - Trial in progress. (2018) (3)
- Mitomycin-C+fluoropyrimidines in heavily pretreated metastatic colorectal cancer: a systematic review and evidence synthesis (2016) (3)
- Neuroendocrine strategy with the pineal hormone melatonin (MLT) to enhance the antitumor activity interleukin-2 (IL-2) (1990) (3)
- [Prognostic predictive factors of the clinical response to immunotherapy with subcutaneous interleukin-2, in patients with metastatic renal carcinoma: analysis of 60 cases]. (1995) (3)
- A broad Italian experience with eribulin mesylate in metastatic breast cancer patients: The ESEMPiO study. (2015) (3)
- An Analysis of the Social and Economic Costs of Breast Cancer in Italy (2021) (3)
- Medical Treatment of Colorectal Cancer in Elderly (>70 Years): Giscad Experience and Future Perspectives (2002) (3)
- Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study. (2014) (3)
- Antibiotic prophylaxis for skin toxicity induced by anti-EGFR agents : a systematic review and meta-analysis Prevention of anti-EGFR related skin rash with tetracyclines (2016) (3)
- Survival benefit with low-molecular-weight heparin in patients with advanced solid tumors: A post hoc analysis of PROTECHT trial. (2014) (3)
- Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: an individual patient data (IPD) analysis (2018) (3)
- This letter was referred to the authors, who respond as follows: (1997) (3)
- LBA23FOLFOX4/XELOX in stage II–III colon cancer: Efficacy and safety results of the Italian Three Or Six Colon Adjuvant (TOSCA) trial (2017) (3)
- Is there a role for maintenance therapy in non-small-cell lung cancer? An emerging issue (2009) (3)
- Patients with metastatic castration-resistant prostate cancer (mCRPC) who are long-term responders (LTR) to the new agent (NA)-based second line: Clinical outcomes and prognostic factors of subsequent treatment with another NA. (2017) (3)
- Endocrinological Study of the Dopaminergic Regulation of Prolactin Release in Metastatic Breast Cancer (1999) (3)
- Contents Vol. 52, 1999 (2000) (3)
- Endocrine Effects of Human Recombinant Interleukin-3 in Cancer Patients (1992) (2)
- Adjuvant Chemotherapy of Colon Cancer (1997) (2)
- Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial (2020) (2)
- [Monitoring of cardiac damage in cancer patients treated with cardiotoxic drugs]. (2013) (2)
- Clinical significance of erythrosedimentation rate in cancer in relation to cytokine production: correlation with high IL-6 and low IL-2 blood concentrations. (1996) (2)
- Malignant Testicular Germ Cell Tumor in Father and Son: A Case Report (1989) (2)
- Multidisciplinary teams for the proper management of patients with genitourinary tumors: When topics set scientific societies’ agenda (2018) (2)
- Neopterin, Soluble IL-2 Receptor and IL-6 Secretion during IL-2 Cancer Immunotherapy: Prognostic Significance in Relation to IL-12 Variations (1997) (2)
- Khorana risk score: Is the body mass index a predictable factor for thromboembolism in European countries? A retrospective analysis. (2012) (2)
- Is it time for everolimus-based combination in castration-resistant prostate cancer? (2016) (2)
- Importance of adherence to guidelines in breast cancer clinical practice. The Italian experience (AIOM) (2011) (2)
- Erratum: The promher study: An observational Italian study on adjuvant therapy for her2-positive, pt1a-b pn0 breast cancer stefania gori (PLoS ONE (2015) 10:9 (e0139650) DOI: 10.1371/journal.pone.0139650) (2015) (2)
- High-risk radically resected gastric cancer patients do not benefit of an adjuvant cisplatin containing regimen (2005) (2)
- Predictors of response to an intensive weekly chemotherapy in advanced gastric cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) (1999) (2)
- Exemestane (Exe) as primary treatment in hormonosensible early breast cancer of the elderly: Preliminary results of a phase II multicenter open Italian study. (2006) (2)
- Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents (2016) (2)
- Blood Levels of Atrial Natriuretic Peptide in Non-Small Cell Lung Cancer and their Changes with Surgery (1992) (2)
- Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study (2016) (2)
- [The cardiovascular toxicity of interleukin-2: the pathogenic mechanisms and treatment]. (1990) (2)
- Studying Predictors of Posttraumatic Growth in Cancer Patients (2011) (2)
- Pineal-Interleukin-2 Interactions and their Possible Importance in the Pathogenesis of Immune Dysfunctions in Cancer (1991) (2)
- Malignancy: Changes in Circulating Immature and Mature Dendritic Cells During IL-2 Cancer Immunotherapy and Their Relation with Lymphocyte Increase and Clinical Response. (2000) (2)
- 708PRESECTION RATE WITH FOLFIRINOX-BASED NEOADJUVANT THERAPY IN LOCALLY ADVANCED/BORDERLINE RESECTABLE PANCREATIC CANCER: A POOLED ANALYSIS OF PUBLISHED DATA. (2014) (2)
- Reply to Letter: "Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies". (2015) (2)
- 5-year results of cisplatin-epirubicin-vinorelbine (PEV) combination as primary chemotherapy in T2-3, N0-2 breast cancer patients: a multicentre phase II study. (2007) (2)
- Double modulation of 5-fluorouracil in advanced colorectal cancer with low-dose interferon-alpha 2b and folinic acid. The "GISCAD" experience. Italian Group for the Study of Digestive Tract Cancer. (1994) (2)
- Interleukin-2 Receptor Positive Cells and Circulating Soluble Interleukin-2 Receptors in Patients with Solid Tumors are not Correlated (1989) (2)
- Modulation of macrophage response to interleukin-2 immunotherapy by interleukin-3 in cancer patients. (1992) (2)
- Efficacy of fourth-line chemotherapy in advanced non-small-cell lung cancer: a systematic review and pooled analysis of published studies (2015) (2)
- Prognostic significance of changes in IL-12 secretion during cancer immunotherapy with IL-2 : Preliminary considerations (1997) (2)
- 823 A full navelbine oral (NVB oral) treatment in combination with cisplatin (P) followed by NVB oral single agent as consolidation therapy in advanced non small-cell lung cancer (NSCLC) (2003) (2)
- 3612 Improving chemotherapy capacity by switching from intravenous to oral vinorelbine: TAMINO, an international time and motion audit (2009) (2)
- Phase III trial of first-line treatment with gemcitabine plus docetaxel versus gemcitabine plus paclitaxel in women with metastatic breast cancer (MBC): A comparison of different schedules and treatment. (2012) (2)
- PARAMOUNT trial: reopening a window to maintenance therapy. (2014) (2)
- [Immunotherapy with low-dose subcutaneous interleukin-2 in metastatic renal carcinoma]. (1993) (1)
- Evidence for Altered Hypothalamic-Hypophyseal-Gonadal Axis in Untreated Patients with Testicular Germ-Cell Tumor (1989) (1)
- Melatonin as a Modulator of Cancer Endocrine Therapy (1997) (1)
- Chemo-hormonal therapy for metastatic breast cancer patients: Treatment strategy (2008) (1)
- Prediction of venous thromboembolism in ambulatory patients with cancer receiving chemotherapy: An expanded thromboembolic risk score model. (2011) (1)
- P-111Final results of the GIDEON (Global Investigational of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) study according to patient etiology: The Italian experience (2015) (1)
- Hypertension and Survival in Renal Cell Carcinoma Treated with anti-VEGFR Agents: A Systematic Review and Meta-Analysis (2017) (1)
- Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: Findings from the 'GISCAD-Alternating schedule' study (2008) (1)
- [Concomitant therapy with cisplatin and radiotherapy in locally advanced tumors of the cervico-facial area]. (1987) (1)
- Long-term results of cancer immunotherapy with subcutaneous low-dose interleukin-2 plus melatonin (1998) (1)
- Sorafenib plus chemotherapy versus chemotherapy alone in advanced pancreatic cancer: A randomized phase II trial. (2010) (1)
- Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy (2020) (1)
- Thymidylate synthase (TS) protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil (5FU) (1999) (1)
- Adjuvant chemotherapy with high dose epirubicin and cyclophosphamide (EC) vs cyclophosphamide, methotrexate, fluorouracil (CMF) in high risk premenopausal breast cancer patients. 97. (1997) (1)
- Adjuvant chemotherapy with high-dose epirubicin and cyclophosphamide vs CMF in high-risk premenopausal breast cancer patients (pts). Prospective randomized phase III trial. (1996) (1)
- Lymphocytosis Decline is not Responsible for Tumor Progression in Cancer Patients Chronically Treated with Interleukin-2 (1994) (1)
- Weekly combination of taxol, 5-fluorouracil and leucovorin (TFL) in advanced pretreated breast cancer patients (1999) (1)
- Effect of fulvestrant treatment on serum VEGF levels in hormone-sensitive metastatic breast cancer patients. (2016) (1)
- Synergistic effect of tamoxifen plus the pineal hormone melatonin(MLT) in inhibiting insulin-like growth factor-I (IGF-I)secretion in breast cancer:a biological study (1994) (1)
- Targeted therapies and other agents as first-line maintenance and beyond: particular benefit in pulmonary adenocarcinoma patients. (2011) (1)
- [Radiotherapy plus a combination of cisplatin and 5-fluorouracil for locally advanced head and neck neoplasms. Study of feasibility and preliminary results]. (1990) (1)
- F21Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis (2016) (1)
- Serum Levels of Melatonin in Cancer Patients and their Relation to Body Sizes (1988) (1)
- Correlation between blood levels of beta-endorphin and T helper/suppressor ratio in patients with solid tumors (1989) (1)
- That Tumor you're Going to Get Tomorrow … maybe: Making an Informed Decision (2015) (1)
- “Misura” Project: A Retrospective Survey on the Use of 5fluorouracil in the Treatment of Colorectal Cancer in 24 Italian Clinical Centers (2002) (1)
- 735 L-Leucovorin (LLV) as a modulator of 5-days 5-fluorouracil (5FU) in advanced colorectal cancer (ACC): High dose (HD) versus low dose (LD) (1995) (1)
- Brio: A European Prospective Observational Study to Assess the Burden of Disease and Treatment in Metastatic Breast Cancer (Mbc) Patients Treated with Oral Vinorelbine (Nvboral) or Intravenous Vinorelbine (Ivvino). (2014) (1)
- Effect of interleukin-12 immunotherapy on endogenous secretion of interleukin-2 in metastatic cancer patients (1998) (1)
- Biochemical Modulation of Fluoropyrimidines: the “Giscad” Studies (1993) (1)
- Natural history of malignant bone disease in non-small cell lung cancer: Preliminary results of a multicenter bone metastasis survey. (2013) (1)
- Lack of Changes in Soluble Interleukin-2 Receptor Serum Levels during Chemotherapy-induced Lymphocyte Damage (1990) (1)
- Effects of Interleukin-2 Immunotherapy on Soluble Lymphocyte Markers in Cancer Patients (1992) (1)
- Gilbert's syndrome and fluorouracil toxicity in colorectal cancer patients: which correlation? (2004) (1)
- Plus Bevacizumab as Conversion Therapy for PatientsWith Initially UnresectableMetastatic Colorectal Cancer (2017) (1)
- Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? (2015) (1)
- Immunobiological effects of interleukin-2, interleukin-12 or interleukin-2 plus interleukin-12 in metastatic cancer patients (1998) (1)
- [Cost-effectiveness of oral ibandronate, i.v. zoledronic acid and i.v. generic pamidronate in the management of metastatic bone disease in breast cancer patients: two parallel studies]. (2008) (1)
- FOLFOX4/XELOX in stage II-III colon cancer: early survival data of the Italian Three Or Six Colon Adjuvant (TOSCA) trial. (2017) (1)
- Relation between Surgery-Induced Prolactin Increase and the Menstrual Cycle Phase at Time of Surgery in Premenopausal Breast Cancer (1991) (1)
- Oral vinorelbine: its role in advanced breast cancer pre-treated with anthracycline and taxane chemotherapies (2011) (1)
- Burden Of Advanced Breast Cancer For Patients And Caregiver In Europe: Comparisons Of Two Treatment Forms Of Vinorelbine, Oral And Intravenous. (2015) (1)
- Opioid Receptors in Human Neoplasms: Growth Hormone and Prolactin Response to Morphine, Met-Enkephalin and Buprenorphine in Cancer Patients (1989) (1)
- Gastrointestinal tumors, colorectal (2012) (1)
- A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial (2022) (1)
- Biochemical modulation of fluoropyrimidines: the "GISCAD" studies. GISCAD (Italian Group for the Study of Digestive Tract Cancer). (1993) (1)
- Machine perfusion of fatty livers at 20° reduces sinusoidal cell and hepatocyte apoptosis respect to conventional cold storage (2009) (1)
- The PARAMOUNT trial in NSCLC: is the amount of benefit clinically meaningful? (2013) (1)
- An Italian Oncology Research to Evaluate Adherence to Clinical Guidelines for Cancer Treatment: The Right Program. (2014) (1)
- 256OWEEKLY DOCETAXEL (WD) VS CMF AS ADJUVANT CHEMOTHERAPY FOR ELDERLY EARLY BREAST CANCER (EBC) PATIENTS (PTS): FINAL RESULTS FROM THE RANDOMISED PHASE 3 ELDA TRIAL. (2014) (1)
- Evaluation of the pineal function in patients affected by solid tumor (1987) (1)
- Anal Squamous Cell Carcinoma Arising on Radio-Dermatitis Cured with Chemotherapy Alone: Case Report (1987) (1)
- 2021 POSTER “The Machine Fear”- Cancer Patients Undergoing Radiotherapy Treatment, an Observational Study (2011) (1)
- Modulation of tumor necrosis factor-alpha (TNF-alpha) toxicity by the pineal hormone melatonin (MLT) in metastatic solid tumor patients. (1995) (1)
- Fulvestrant in the treatment of HER2-positive advanced breast cancer (ABC) (2007) (1)
- Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer? (2014) (1)
- Signet-ring cell carcinoma of the rectum and synchronous renal cell carcinoma in a young man (2016) (1)
- Zinc levels in serum during subcutaneous interleukin-2 immunotherapy of cancer (1995) (1)
- Improved preservation of fatty liver by machine perfusion at 20 °C respect to conventional cold storage: Biochemical, histochemical and ultrastructural approaches (2007) (1)
- C17Prognostic role of body mass index (BMI) in patients with metastatic castration resistant prostate cancer (mCRPC) receiving chemotherapy: PRO-BMI study (2016) (1)
- T-30 Preservation of obese rat livers by subnormothermic machine perfusion protects dipeptidylpeptidase–IV activity and expression in the biliary tree (2012) (1)
- Erratum: Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer (British Journal of Cancer (2004) 92 (24-29) DOI: 10.1038/sj.bjc.6602276) (2005) (1)
- Antiangiogenetics-related hypertesion: a class-effect adverse event or therapy response mark? an emerging topic (2015) (0)
- A32Clinical and pathological factors predicting long-term disease control with lapatinib and capecitabine for patients with HER2 positive metastastic breast cancer: results from a multicenter retrospective study (2015) (0)
- Normalization of idiopathic arterial hypertension following cancer immunotherapy with interleukin-2. (1994) (0)
- BOOST: a phase 3 trial of sorafenib vs. best supportive care in first line treatment of hepatocellular carcinoma in patients with deteriorated liver function (2021) (0)
- 1849 Italian observational study of Eribulin Mesylate in patients with advanced breast cancer: ESEMPiO study (2015) (0)
- 583 Treatment of interferon-alpha 2A(IFN)-induced thrombocytopenia by the pineal neurohormone melatonin (MLT) (1995) (0)
- [Costs, disease management and DRG]. (2001) (0)
- Sense of coherence and coping: their roles in promoting well-being in cancer patients (2009) (0)
- [Immunotherapy for metastatic renal carcinoma with interleukin-2 in a subcutanous administration schedule of short duration. Subcutaneous IL-2 in renal carcinoma]. (1997) (0)
- Acknowledgement of reviewers 2014 (2014) (0)
- L11Hepatocellular Carcinoma In Elderly Patients: final results of The Italian Cohort Of GIDEON (Global Investigational of therapeutic DEcisions in HCC and of its treatment with sorafeNib) Study (2015) (0)
- Cancer as risk factor for bleeding during Warfarin treatment (2018) (0)
- Redemption sequences in stories of cancer patients: Their relationship with adversarial growth (2009) (0)
- Locally advanced breast cancer (2006) (0)
- F01*Dose-dense adjuvant chemotherapy, treatment-induced amenorrhea and overall survival in premenopausal breast cancer patients: a pooled analysis of the MIG1 and GIM2 phase 3 studies (2016) (0)
- Reviewer Acknowledgements 2017 (2017) (0)
- N07Adherence to WHO pain guidelines in a community hospital (2015) (0)
- 9034 Medical treatment choices of over 1000 Italian patients affected by stage IIIB-IV NSCLC in routine clinical practice: results from the observational "SUN" (Survey on the lUng cancer maNagement) study on behalf of SUN study Group (2009) (0)
- Guilty feeling in smokers with lung cancer: A psychological study (2008) (0)
- The HERBA trial: a retrospective study on patients (pts) with HER2-positive (HER2+ve) breast cancer (BC) and brain metastases (BMs). (2017) (0)
- Effect of Interferon-Alpha on Soluble Interleukin-2 Receptor and Tumor Necrosis Factor Increase during Immunotherapy with Interleukin-2 (1992) (0)
- Prognostic value of neutrophil-lymphocite ratio in resected high risk colorectal cancer: An analysis of adjuvant TOSCA trial. (2018) (0)
- Anxiety: A psychological observational study before mammography screening (2008) (0)
- Molecular Characterization May Be of PARAMOUNT Importance (2014) (0)
- A new docetaxel (DOC)-based triplet regimen does not improve the outcome of metastatic (M) or locally advanced (LA) gastric cancer (GC) as compared with an epirubicin (EPI) standard triplet regimen: A GISCAD trial (2019) (0)
- Khorana risk score and PROTECHT risk score as prediction models of venous thromboembolism in cancer outpatients receiving chemotherapy: a retrospective analysis (2012) (0)
- Efficacy and safety of bevacizumab in elderly or unfit patients with metastatic colorectal cancer: A systematic review and meta-analysis. (2016) (0)
- Serum Levels of Soluble Interleukin-2 Receptors and their Relation to CD4/CD8 Ratio in Patients with Advanced Solid Tumors (1989) (0)
- 171PComposite index of risk shows that benefit from adjuvant dose dense chemotherapy is not confined to triple negative breast cancer (2017) (0)
- 372 How Reliable is the Measurement of Pain in Oncological Day Hospital (DH) Patients (2012) (0)
- Fulvestrant: a new opportunity in advanced breast cancer (ABC) (2006) (0)
- L10Final results of the gideon study according to patient etiology: The italian experience (2015) (0)
- Influence of presurgical idiopathic hyperprolactinemia on relapse rate in operable breast cancer (1995) (0)
- Is mammography screening anxiety related to personal coping style (2008) (0)
- [PP.06.11] ANTIANGIOGENETICS AND HYPERTENSION: EPIDEMIOLOGY AND BASAL FEATURES OF PATIENTS (2016) (0)
- [Lymphocyte levels before treatment with subcutaneous interleukin-2 and during maintenance treatment in relation to the clinical efficacy in metastatic renal carcinoma]. (1995) (0)
- R44Cancer Registries Underestimate both the Type of Disease and also Number of Cases due to Pollution (2015) (0)
- How Italian oncologists cope with end-of-life care: A pilot study (2008) (0)
- Subject Index Vol. 60, 2001 (2001) (0)
- Contents Vol. 68, 2005 (2005) (0)
- Colorectal Cancer With Low-dose Interferoma2b and Folinic Acid. The "GISCAD" Experience (1994) (0)
- 3027 POSTER Emotions, Picture and Radiotherapy (2011) (0)
- 2127 POSTER Activity of Fulvestrant in patients with HER2-positive advanced breast cancer (2007) (0)
- F4320 years single center experience with testicular cancer (2015) (0)
- 4202 POSTER Drawings as a Mirror of the Couple Relationship (2011) (0)
- Abstract P5-19-25: Multi-institutional retrospective analysis of clinical and pathological factors predicting resistance to lapatinib-based therapy in HER2 positive metastatic breast cancer (HER2+ MBC) (2015) (0)
- Contents Vol. 63, 2002 (2002) (0)
- Efficacy and safety of bevacizumab combined with fluoropyrimidine monotherapy in unfit or older metastatic colorectal cancer patients: A systematic review and pooled-analysis. (2016) (0)
- N09Empathic communication for reduction of pain perception and anxiety in patients implanted central venous accesses for cancer therapy: an experience of 51 cases (2016) (0)
- TUMOUR NECROSIS FACTOR-ALPHA (TNF-ALPHA ) BLOOD LEVELS IN RELATION TO THE ACTIVITY OF THE PINEAL GLAND IN CANCER PATIENTS (1996) (0)
- Treatment effectiveness in advanced breast cancer patients in Italy: Ten years experience. (2013) (0)
- Second line chemotherapy on advanced colo-rectal tumors: Evaluation of mitomycin C (MMC) activity (1993) (0)
- 532 Is Axillary Dissection Still Useful in Node-negative Early Breast Cancer? (2012) (0)
- A randomised phase II study of cetuximab plus gemcitabine/cisplatin combination in advanced pancreatic cancer (APC) (2007) (0)
- [Erythropoietin today? Contrary opinions]. (2006) (0)
- [Adjuvant therapy of colon cancer. State of the art and future perspectives]. (1999) (0)
- Sequential administration of new agents (NAs) after docetaxel (DOC) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Impact of disease control (DC) duration in second line on the subsequent line outcomes. (2016) (0)
- Real-life utilization of genomic testing for invasive breast cancer patients in Italy and France reduces chemotherapy recommendations. (2018) (0)
- Pain Management in Eight Italian Oncological Care Centres (2012) (0)
- Effect of mastectomy versus mastectomy plus adjuvant ovariectomy on prolactin response to TRH in breast cancer. (1990) (0)
- Currentdataoftargetedtherapies forthetreatmentoftriple-negative advancedbreastcancer: empiricismorevidence-based? (2009) (0)
- Contents Vol. 71, 2006 (2007) (0)
- [Cardioangioimmunology: the immune implications in the principle cardiovascular pathologies]. (1991) (0)
- A Thrombotic Biomarker-Based Risk Assessment Scoring Model for Disease Recurrence in Breast Cancer Patient Candidate to Systemic Chemotherapy (2019) (0)
- Real-Life Utilization of the 21-Gene Assay in Italian Clinical Practice (2018) (0)
- TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape? (2016) (0)
- Hemostatic biomarkers levels for the identification of cancer patients at higher VTE risk enrolled in the HYPERCAN study (2018) (0)
- Subject Index Vol. 68, 2005 (2005) (0)
- Letrozole (LE)-Vinorelbine (VIN) as first-line treatment in advanced breast cancer (ABC) patients: Preliminary results of a multicentre phase II study (2004) (0)
- Thromboembolic risk and survival with Khorana score in resected colorectal cancer patients: Subgroup analysis from the adjuvant TOSCA trial. (2018) (0)
- P-450 Gemcitabine-epidoxorubicin-cisplatin (GEP) as a new tripletcombination chemotherapy in patients with stage IIIB-IV non small cell lung cancer (NSCLC). A dose finding study (2005) (0)
- Molecules, Drugs, and First-Line Therapies: A Guide for the Cardiologist (2017) (0)
- Contents Vol. 60, 2001 (2001) (0)
- Acute dyspnea due to right phrenic palsy during infusional chemotherapy. (2004) (0)
- Abstract P1-14-04: Overall survival in metastatic breast cancer patients in the third millennium: Results of an Italian study (2018) (0)
- 9126 POSTER Anaemia Risk With Anti-EGFR Agents in Advanced Non Small Cell Lung Cancer – a Meta-analysis of 10 Trials (2011) (0)
- Adjuvant endocrine treatment in premenopausal patients with breast cancer: Clinical practice in an Italian cancer center. (2013) (0)
- [HCF-ANMCO/AICPR/GIEC/ITAHFA/SICOA/SICP/SIMG/SIT Cardiological Societies Council Consensus document: Anticoagulant therapy in venous thromboembolism and atrial fibrillation of the patient with cancer. Current knowledge and new evidence]. (2020) (0)
- Pre-Chemotherapy Levels of Hemostatic Biomarkers and Prediction of Prognosis in Newly Diagnosed Metastatic Cancer Patients from the Hypercan Study (2018) (0)
- C15Over the years change in prostate cancer management through the multidisciplinary team at a community hospital (2016) (0)
- Natural history of malignant bone disease in gastric cancer: Final results of a multicenter bone metastasis survey. (2013) (0)
- Skin Rash and Outcome in Colorectal Cancer (CRC) Patients Treated with Anti-Egfr Monoclonal Antibodies (2012) (0)
- Ondansetron Does not Stimulate Prolactin Release in Breast Cancer Patients (1994) (0)
- 4161 ORAL Cancer – a Challenge for the Whole Family (2011) (0)
- The Greta study: generating real-world evidence about bevacizumab treatment of metastatic Colorectal Cancer by linking Cancer registries and healthcare databases in Italy (2017) (0)
- Weekly epirubicin plus low-dose interleukin-2 subcutaneous therapy in breast cancer: preliminary immunobiological results. (1994) (0)
- F17The STAR score predicts prognosis in Luminal-like breast cancer patients independently from dose-dense adjuvant chemotherapy (2016) (0)
- Soluble Interleukin-2 Receptor Levels in Hodgkin's Disease: Preliminary Considerations about their Prognostic Significance (1988) (0)
- Biological significance of interleukin-6 secretion on cancer immunotherapy with interleukin-2 (1996) (0)
- The organismic-valuing theory of adversarial growth: A longitudinal study of cancer patients (2009) (0)
- Abstract P1-09-12: Dose dense adjuvant chemotherapy in patients with early breast cancer: Differential treatment effects according to composite index of benefit (2017) (0)
- From PTSD to PTG: Studying predictors of Post-Traumatic Growth in Cancer Patients (2008) (0)
- Hospital effect on 3-years-survival in patients undergone to lung tumor surgery: a real-world study. (2019) (0)
- Antiangiogenetic-induced hypertension and improved outcome in cancer patients. (2017) (0)
- Subcutaneous low-dose IL—2 with the pineal hormone melatonin (MLT): a new effective therapy of most advanced solid tumors (1995) (0)
- Italy GIDEON final analysis Sorafenib-treated patients: prognostic value of baseline characteristics and staging systems (2014) (0)
- The prethrombotic state induced by anticancer drugs therapy in women with breast cancer (1992) (0)
- Effects of granulocyte colony stimulating factor on the specific macrophage marker neopterin in cancer patients (1995) (0)
- [Bilateral ectopic pheochromocytoma with renovascular hypertension. Report of a case (author's transl)]. (1981) (0)
- The role of social support and coping strategies in predicting post-traumatic growth in cancer patients: A longitudinal study (2010) (0)
- Oxaliplatin (L-OHP) in combination with leucovorin and bolus-continuous infusion 5fluorouracil (LV5FU2) in advanced colorectal cancer (ACC) pretreated with 5fu (1999) (0)
- Abstract P5-15-17: Platinum salts in advanced breast cancer: A systematic review and meta-analysis of randomized clinical trials (2017) (0)
- 1161 POSTER Smoking and feelings of guilt in lung cancer patients: a psychological study (2007) (0)
- Neuroendocrine modulation of il-2 antitumor activity. (1996) (0)
- Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy (2020) (0)
- The presence of bone (BM) and concomitant non-bone metastases (cNBM) significantly worsens the 2-year overall survival (OS) in breast cancer (BC) patients (PTS): Update of results in the moon study (2005) (0)
- 3071 POSTER Risk of Anaemia With Targeted Therapies – a Meta-analysis of Randomized Trials in Solid Tumours (2011) (0)
- [PP.13.03] ANTIANGIOGENETICS AND HYPERTENSION: MANAGEMENT AND PROGNOSTIC IMPLICATIONS (2016) (0)
- FSH and LH responses to LHRH in patients with testicular germ-cell tumor (TGCT) (1987) (0)
- Phase II, multicentre study evaluating cisplatin (P), epirubicin (E) and vinorelbine (V) as first line chemotherapy (CHT) in advanced breast cancer (ABC): A new promise. (2004) (0)
- Thrombotic Risk Assessment in a Prospective Cohort of Newly Diagnosed Ambulatory Cancer Patients Candidate to Chemotherapy (2019) (0)
- Skeletal-related events (SREs) are common in patients with bone metastasis from renal cell carcinoma ( N = 398). (2013) (0)
- B13Clinical and pathological features of rare histological exocrine pancreatic cancers (PCs): a retrospective multicentric analysis (2016) (0)
- P-110Hepatocellular carcinoma in elderly patients: Final results of the Italian cohort of GIDEON study (2015) (0)
- Clinicians’ attitudes and preferences in choosing the first line drug for metastatic castration resistant prostate cancer (mCRPC): Preliminary results from a multicenter Italian study after the introduction of abiraterone acetate (AA) in the clinical practice. (2016) (0)
- Adjuvant hormonal therapy and fertility preservation in premenopausal breast cancer: a survey among Italian oncologists. (2015) (0)
- Hormonal therapy of advanced adenocarcinoma of the pancreas with somatostatin and GNRH analogs (1993) (0)
- Malignant Ascites: Diagnosis and Treatment (2012) (0)
- Lobular Carcinoma of the Breast and Utility of Oncotype Dx®: a Retrospective Decision Impact Analysis. (2022) (0)
- Dose-dense FEC followed by dose-dense ixabepilone as neoadjuvant treatment for breast cancer patients: a feasibility study. (2013) (0)
- Post-traumatic growth: An adaptive cognitive-emotional engagement (2009) (0)
- Abstract OT1-01-05: PAINTER: Evaluation of eribulin tolerability and correlation between a set of polymorphisms and neuropathy in patients with metastatic breast cancer (2017) (0)
- Ambulatory Patients with Metastatic or Locally Advanced Cancer: is Body Mass Index ≥ 35 A Risk Factor for Thromboembolism also in European Countries? (2012) (0)
- New biweekly combination of trastuzumab, docetaxel, and gemcitabine for HER2-positive metastatic breast cancer: First early results from a phase II multicentric trial on behalf of Gruppo Oncologico Italia Meridionale. (2009) (0)
- Phase II of oral vinorelbine (NVB oral) in combination with Cisplatin (P) followed by NVB oral single agent as consolidation therapy in advanced non small-cell lung cancer (NSCLC): A Patient's Benefit Analysis. (2004) (0)
- 2075 POSTER Does the estrogen receptor status influence survival of pCR breast cancer (BC) patients (pts) after primary chemotherapy (CHT)? Results of a multicenter study (2007) (0)
- 5th International multidisciplinary course on iron anemia, 31st March–1 April 2017, Florence, Italy (2017) (0)
- Turn on the TORCH before treat your patients: a lesson from a first line study in advanced NSCLC. (2012) (0)
- Thrombin Generation and D-Dimer Significantly Predict for Early Disease Progression and Mortality in Patients with Gastrointestinal Cancer (2020) (0)
- Original article Sexual dysfunction in treated breast cancer patients (2005) (0)
- The Impact of Anemia in Advanced Solid Tumors Treated with Sorafenib (SO) and Sunitinib (SU): A Pooled Analysis of 6 Trials (2012) (0)
- Acknowledgement of reviewers 2015 (2015) (0)
- Germline variants and clinical outcomes of high-risk stage II and stage III colon cancer patients treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy: a pharmacogenetic ancillary study to TOSCA trial. (2017) (0)
- Prognostic role of tumor budding in stage II colorectal cancer: A meta-analysis of published studies. (2015) (0)
- ANEMIA ASSOCIATED WITH NON-CYTOTOXIC AGENTS (PD-[L]1, PARP AND OTHER TARGETED THERAPIES): A REVIEW OF THE LITERATURE (2019) (0)
- A new–old problem in medically ill: anaemia of chronic disease (2015) (0)
- 445TiP VIVA trial: A randomized phase II study of adjuvant regorafenib plus durvalumab in stage IV colorectal cancer patients achieving the no evidence of disease state (2022) (0)
- PRO-BMI study: prognostic role of body mass index (BMI) in metastatic castration resistant prostate cancer (mCRPC) patients receiving chemotherapy. (2016) (0)
- 03 / SUCROSOMIAL IRON: A NEW ALTERNATIVE FOR FIRST LINE ORAL SUPPLEMENTATION IN CANCER PATIENTS WITH IRON-DEFICIENCY ANEMIA (2018) (0)
- 576PPHARMACOGENETIC PROFILING FOR TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINES. FINAL REPORT FROM AN ANCILLARY PROTOCOL TO THE TOSCA (THREE OR SIX COLON ADJUVANT) TRIAL. (2014) (0)
- 1085 POSTER The Longitudinal Trajectory of Post-Traumatic Growth: a Longitudinal Study (2011) (0)
- Neuroimmunomodulation(NIM) and IL-2 immunotherapy: A neuroe ndocrine combination with IL-2 and melatonin(MLT) in advan ced solid tumors (1993) (0)
- Subject Index Vol. 52,1995 (1995) (0)
- PO-83 Assessment model for thrombotic risk in a prospective cohort of newly diagnosed metastatic cancer outpatient candidates for chemotherapy (2021) (0)
- 719 Doxifluridine in advanced colorectal carcinoma. Parallel multicentre randomized phase II trial (1995) (0)
- 2*Dihydropyrimidine dehydrogenase (DPYD) gene polymorphisms profiling in colon cancer patients treated with adjuvant chemotherapy in the randomized phase III TOSCA trial (2016) (0)
- Psychological and physical support after breast cancer surgery (BCS): a new comprehensive approach (2001) (0)
- Which is the appropriate adjuvant endocrine therapy for premenopausal patients with breast cancer? (2015) (0)
- D48Monoinstitutional retrospective analysis of metronomic capecitabine (mc) schedule in the treatment of metastatic colorectal cancer (2016) (0)
- Therapeutic use of the pineal hormone melatonin in human neoplasms update results (1994) (0)
- Subject Index Vol. 71, 2006 (2007) (0)
- P09Second-opinion. Impact on Italian Oncologists (2015) (0)
- PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy (2021) (0)
- 8th International Multidisciplinary Course on Iron Deficiency, Stresa (Italy), 21-22 October 2022. (2023) (0)
- P26Find yourself with a smile (2015) (0)
- Subject Index Vol. 63, 2002 (2002) (0)
- Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer (2015) (0)
- Immune-related adverse events (irAEs) and survival in solid tumors treated with immune checkpoint inhibitors (ICIs): A systematic review and meta-analysis. (2019) (0)
- P21First visit is never forgotten (2015) (0)
- N30The role of medical department in the management of Breast Cancer patients: a series review (2015) (0)
- S06Efficacy of antibiotic prophylaxis with tetracyclines for EGFR induced skin rash: a systematic review and pooled-analysis of 13 studies (2016) (0)
- Is there any difference between microscopic residual disease (pTm) and no invasive disease (pT0) in the breast when there is residual disease in the axilla after primary chemotherapy for breast cancer (BC)? Results of a multicenter study (2007) (0)
- Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) pts receiving a new agent (NA)-based third line treatment: Preliminary results from a multicenter Italian study. (2017) (0)
- Sunitinb, hypertension and renal function: a monocentric experience. (2017) (0)
- Abstract P5-18-05: The Promher Study: An observational Italian study on HER2+ve, pT1a-b, pN0, M0 breast cancer (BC) patients (pts) (2015) (0)
- Author Index (1998) (0)
- Severe Hypotension in Disseminated Colon Cancer Due to a Possible Decreased Dopamine Brain Content: A Case Report (1990) (0)
- breast cancer chemotherapy, treatment-induced and overall survival in breast cancer patients: a pooled analysis of the MIG1 and GIM2 phase 3 studies (2016) (0)
- Issue Information‐ToC (2019) (0)
- 828PBONE METASTASES FROM RCC ARE NOT ALWAYS ASSOCIATED WITH A POOR PROGNOSIS. (2014) (0)
- Reactivation of a normal endogenous secretion of interleukin-2 in metastatic cancer patients by a chronic subcutaneous injection of interleukin-2. (1996) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Sandro Barni?
Sandro Barni is affiliated with the following schools:
